QuidelOrtho Corp’s Schedule 13G/A reports FMR LLC and Abigail P. Johnson as reporting persons, each with beneficial ownership of 3,950,168 shares of common stock, or 5.8% of the class. FMR LLC reports sole voting power over 3,945,240 shares and sole dispositive power over 3,950,168 shares. Abigail P. Johnson reports 0 sole voting power and sole dispositive power over 3,950,168 shares. Both report 0 shared voting and dispositive power. The disclosure says other persons may have rights to dividends or sale proceeds, but no other person’s interest exceeds 5% of the outstanding common stock.
QuidelOrtho Corporation (QDEL) amended its existing credit agreement on September 23, 2026, resetting financial covenant levels through the fiscal quarter ending September 30, 2029. The maximum Consolidated Leverage Ratio and minimum Consolidated Interest Coverage Ratio are 5.50 to 1.00 and 2.25 to 1.00, respectively, on or prior to July 2, 2028; 5.00 and 2.50 on October 1 or December 31, 2028; 4.50 and 2.75 on April 1 or July 1, 2029; and 4.25 and 3.00 on or after September 30, 2029.
Initial rates for the Term Loan A Facilities and Revolving Credit Facility run from the Amendment effective date until the first business day after the Administrative Agent receives the compliance certificate for the quarter ending September 28, 2026: 1.50% per annum for base-rate loans and 2.50% for Term SOFR loans. Thereafter, leverage-based ranges are 0.75% to 2.00% for base-rate loans and 1.75% to 3.00% for Term SOFR loans; the unused commitment fee ranges from 0.20% to 0.40% per annum. Term Loan B interest is unchanged.
QuidelOrtho Corp (QDEL) reported that Chief Human Resources Officer Ronald Lee Bowman had restricted stock units convert into common stock on September 15, 2026. 2,566 restricted stock units were exercised into 2,566 shares of common stock, and 921 shares of common stock were delivered to the issuer at $10.63 per share to satisfy tax withholding obligations related to this vesting. Each restricted stock unit represents one share of QuidelOrtho common stock, and no transactions were reported as made under a Rule 10b5-1 trading plan.
QuidelOrtho Corp (QDEL) reported that EVP Global Portfolio Management & Marketing Bryan Michael Hanson had 446 restricted stock units vest on August 15, 2026, converting into 446 shares of common stock. To satisfy related tax withholding obligations, 162 common shares were withheld by the company at $14.30 per share. Following this vesting event, the reported balance of these specific restricted stock units is 0.
Newtyn Management, LLC and Newtyn TE Partners, LP report their beneficial ownership of QuidelOrtho Corporation common stock in this amended Schedule 13G. As of June 30, 2026, Newtyn Management may be deemed to beneficially own 6,625,000 shares, representing 9.7% of QuidelOrtho’s common stock outstanding.
Within this amount, Newtyn TE Partners directly holds 4,266,500 shares, or 6.3% of the class, and Newtyn Partners, LP holds the remaining 2,358,500 shares. The reporting persons state sole voting and dispositive power over their reported holdings, based on 68,190,989 shares outstanding as of April 28, 2026.
T. Rowe Price Investment Management, Inc. reports beneficial ownership of 1,743,563 shares of QuidelOrtho Corp common stock, representing 2.6% of the class. The firm holds sole voting and dispositive power over all reported shares and states that its ownership is 5 percent or less of the class.
Invesco Ltd. filed as a significant shareholder of QuidelOrtho Corp, reporting beneficial ownership of 3,473,432 shares of common stock, representing 5.1% of the class. Invesco, a Bermuda company, reports this stake in its capacity as a parent holding company to its investment advisers.
Invesco has sole voting power over 3,455,098 shares and sole dispositive power over 3,473,432 shares, with no shared voting or dispositive power. The shares are held of record by clients of Invesco Ltd., and no single client has more than 5% economic ownership. Subsidiaries identified in connection with this holding are Invesco Advisers, Inc. and Invesco Capital Management LLC.
QuidelOrtho reported second quarter 2026 results with total revenue of $630.9 million, a 2.8% year-over-year increase, and a GAAP net loss of $92.9 million, or a loss of $1.36 per diluted share. Adjusted EBITDA was $129.3 million, a 20.5% margin, as Labs revenue grew 4% and Point of Care revenue grew 16%.
Revenue excluding China rose 6.1%, while China revenue declined 18.7%, reflecting pressure from proposed In Vitro Diagnostics pricing changes. QuidelOrtho cut its 2026 outlook to $2.52–$2.60 billion in revenue, $540–$560 million in adjusted EBITDA and $0.65–$0.90 adjusted EPS, and withdrew free cash flow guidance after using $143.6 million of operating cash in the first half.
Neuberger Berman Group LLC and Neuberger Berman Investment Advisers LLC report beneficial ownership of QuidelOrtho Corp common stock on a Schedule 13G/A. Neuberger Berman Group LLC is reported as beneficially owning 3,381,189 shares, representing 4.9% of the outstanding common shares.
The filing indicates no sole voting or dispositive power, with shared voting power over 2,720,194 shares and shared dispositive power over 3,381,189 shares. The report explains that various Neuberger Berman fiduciary entities may be deemed to beneficially own these securities under Exchange Act Rule 13d-3, but each entity disclaims beneficial ownership under Rule 13d-4. Securities managed by NB Alternatives Advisers LLC and other subsidiaries separated by an information barrier are expressly excluded.